You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)委任毛力教授為首席醫學官
格隆匯 05-10 16:57

格隆匯 5 月 10日丨中國生物製藥(01177.HK)宣佈,毛力教授已獲公司委任為首席醫學官,主要負責制定創新產品研發策略、指導創新產品管線的臨牀開發和轉化研究、推動國際合作。

毛力教授擁有逾35年的腫瘤學臨牀實踐、基礎研究及領導經驗,創建了美國強生公司橫跨三大業務領域的全球肺癌研究中心,是腫瘤領域的世界知名專家。他在南京醫科大學獲得臨牀醫學學位,並在美國梅奧醫院及約翰霍普金斯大學醫學院完成博士後研究及學習。毛教授榮膺美國德州大學MD安德森癌症中心的終身教授,並曾為美國馬里蘭大學腫瘤和診斷學系系主任。毛教授在腫瘤分子生物學機制研究、分子診斷及精準化治療等領域建樹甚豐,學術造詣深厚;發表了SCI(科學引文索引)論文200多篇,論文被引用超過25,000次。他曾擔任多本國際專業雜誌的編輯及編委以及美國國立衞生研究院多項基金的評審組成員。毛力教授曾受聘為國家高層次人才計劃專家、上海交通大學醫學院長江學者講座教授,並先後擔任美國強生公司及其他大型藥企的高級管理職務,領導開展了多項臨牀註冊研究,完成了多個新藥證書的申報。

集團一直非常重視新藥研發和創新。相信隨着毛教授的加盟,其卓越的科研能力、豐富的管理經驗以及為全球業界普遍稱道的學術造詣,將為本集團在腫瘤領域為主的新品研發、技術轉化、國際合作提供極大助益;同時也將對本集團的創新驅動和國際化戰略有所貢獻。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account